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Abstract
Objective
Characterize the onset and timing of cognitive decline in PD from the first recognizable stage of cognitively
symptomatic PD - mild cognitive impairment (PD-MCI) - to PD dementia (PDD). Thirty-nine participants
progressed from PD to PDD and 25 remained cognitively normal.

Method
Bayesian estimated disease-state models described the onset of an individual’s cognitive decline across 12
subtests with a changepoint.

Results
Subtests measuring working memory, visual imagery, and crystalized memory changed significantly 3–5 years
before their first non-zero CDR and progressively worsened from PD to PD-MCI to PDD. Crystalized memory
deficits were the hallmark feature of imminent conversion of cognitive status. Episodic memory tasks were not
sensitive to onset of PD-MCI. For cognitively intact PD, all 12 subtests showed modest linear decline without
evidence of a changepoint.

Conclusions
Longitudinal disease-state models support a prodromal dementia stage (PD-MCI) marked by early declines in
working memory and visuospatial processing beginning 5 years prior to clinical diagnosis of PDD. Cognitive
declines in PD affect motor ability (bradykinesia), working memory and processing speed (bradyphrenia)
resulting in PD-MCI where visuospatial imagery and memory retrieval deficits manifest before eventual
development of overt dementia. Tests of episodic memory may not be sufficient to detect and quantify
cognitive decline in PD.

Keywords
Alzheimer’s disease, Parkinson’s disease with dementia, Parkinson’s disease/Parkinsonism, Longitudinal,
Piecewise regression, Bayes Theorem

Introduction
Clinical research in Parkinson’s disease (PD) has demonstrated that a majority of the patient population with PD
will develop an associated dementia marked by declines in episodic and working memory, visuospatial
processing, executive functioning, and functional abilities.1–13 Building on existing consensus criteria14–19 a
taskforce sponsored by Movement Disorders Society20,21 has established diagnostic criteria for an early stage
cognitive impairment associated with PD (PDD) coined Mild Cognitive Impairment (PD-MCI). Analogous to
criteria for MCI in Alzheimer disease, PD-MCI connotes the earliest clinically recognizable stage of PDD - a
prodrome of the dementia state where symptoms first appear eventually worsening over time.22 Identification
of a prodromal phase is important so that interventions can be administered at a time when they are most
effective, before the disease progresses and damage becomes widespread.23 The establishment of the task force
and potential standardization of the PD-MCI has initiated debate about the composition of this prodromal stage.
For instance, are there specific domains that are early milestones in the progression of the dementia? What are
the cognitive and functional domains that clinicians need to assess to detect the dementia as its symptoms first
appear? What extent of functional impairment is needed to distinguish PD-MCI from PDD? Since criteria for PDMCI were published a discussion has developed regarding subtest sensitivities,24,25,26 cutpoints that should be
applied,25,27,26 and whether or not there exists a single domain PD-MCI.24 The burgeoning literature suggests that
extensive psychometric work will need to be conducted by many centers.

In a well-controlled longitudinal study, we previously demonstrated that cognitive ability declined in PD several
years prior to detection of any overt neurocognitive or functional symptoms.12 A visuospatial composite score
based on factor analysis was the most potent harbinger of a subsequent dementia diagnosis, occurring about 3
years prior on average. However a similar decline on the visuospatial factor was also witnessed in Alzheimer’s
disease28,29 (although not as pronounced or as early) and declining scores were also prominent in PD without
dementia12 (PDND). Visuospatial processing ability was a sensitive indicator but lacked specificity. The previous
study used factor scores that were derived from large patient samples with and without Alzheimer’s dementia,
applied to patients with PD. The result was an accurate test of PD cognitive performance relative to Alzheimer’s
disease-specific indices, not specific to PD cognitive decline.
Since our first report we have developed more sensitive analytic techniques to measure disease transition that
index profiles of neuropsychological performance of patients transitioning from cognitive intact PD to cognitive
symptomatic PD, permitting characterization of a PD-MCI stage. In this study, we applied a novel analytic
perspective on the diagnostic canonization of PD-MCI using a Bayesian estimated disease-state model
(multiphase random changepoint model; MRC) 30–32 to determine the onset of decline on an individual-byindividual basis yielding precise estimates of disease onset. Disease state models describe the longitudinal
trajectory of scores with a changepoint. Before the changepoint, cognition tends to be relatively stable. After
the changepoint, cognitive begins an accelerating decline. Thus the longitudinal trajectories of cognitively
normal individuals who eventually develop dementia start shallow and then decline precipitously. The
placement of the changepoint marks the onset of a disease process. By using individual specific changepoints we
are better able to capture disease progression by allowing the individual’s performance to vary over time due to
multiple disease processes. These models are flexible enough to estimate the state of disease progression on an
individual-by-individual basis. This report extends our previous work28,29 that compared the declining cognitive
trajectories in PD to AD that showed PDD follows similar overall trajectories but starts in a different mix of
subtests than does AD. Here we examine cognitive profiles of PD patients followed for more than 7 years on
average to characterize the onset and timing of declining cognitive performance. We hypothesized that
cognitive decline from PD to PDD passes through a definable phase of mild cognitive impairment (PD-MCI) with
the greatest decline in visuospatial, working memory and perceptual speed domains and that examination of
specific subtests with a model based on individual differences for disease onset would reveal earlier deficits.

Methods
Participants
Archival data were examined two groups of volunteers enrolled in a longitudinal study of healthy aging and
dementia at the Knight Alzheimer Disease Center at Washington University. The first group remained cognitive
intact in all assessments (PDND, n=25). The second group developed PDD (n=39). All participants were recruited
either from (1) a project to examine clinical outcomes in PD8 or (2) were originally enrolled as nondemented
controls and later developed PD. For this later group, only those times-of-assessment where PD was diagnosed
were included. Thus PD patients reported here are a subset of a larger clinical cohort reported previously1,2,4,5,12
with the important distinction of having been assessed at least 3 times so changepoint models have sufficient
repeated measures data to be estimated. Thus all PD participants enrolled without cognitive impairment (i.e.,
CDR 0); and there were sufficient number of repeated measures to estimate MRC change points. Disorders that
can result in other types of dementia (e.g., cerebrovascular disease, frontal lobe syndromes) were excluded.
Medication of PD symptoms was managed outside of the current study, but by study end all PD participants
(PDD and PDND) were placed on dopaminergic agonists. All participants spoke English and lived in the greater St.
Louis metropolitan area. The Washington University Human Studies Committee approved all procedures.

Clinical evaluation
Detailed information about the clinical assessment and the diagnostic criteria for PD was based on United
Kingdom PD criteria.33 The diagnosis of PDD was based on DSM-IV criteria and a Clinical Dementia Rating (CDR34)

≥ 0.5, suggesting earliest recognizable stage of cognitive impairment. None of the PDND participants received a
diagnosis of dementia or a CDR > 0 at any time of assessment.
Standardized assessments of PD such as Hoehn and Yahr35 stages or Unified Parkinson Disease Rating Scale
(UPDRS) motor scores36 were not available for all cases. Therefore, in order to control for bradykinesia, we used
Crossing Off37, a psychometric assessment of simple motor speed, as a gross index of motor slowing across all
groups. Although not diagnostic of PD, Crossing Off accurately reflects motor slowing associated with PD (Table
1) and was used here as a psychometric (not clinical) control variable.
Table 1. Demographic Means at the first measurement time (SD)
Stable (n=25) Progressed (n=39)
Age (yrs)
69.3 (7.4)
71.6 (7.5) *
Education (yrs)
13.6 (2.7)
15.4 (3.2) †
Gender (% men)
80
74.4 *
a
Crossing Off (Simple Motor Speed) 141.8 (30.1)
142.5 (33.1)
Cognitive Battery
Logical Memory
7.2 (2.8)
7.0 (2.6)
Information
21.2 (4.7)
20.4 (3.9)
Boston Naming
54.3 (4.9)
55.2 (3.3)
Associate Learning
12.9 (3.2)
13.0 (3.9)
Trailmaking A (sec)b
51.9 (23.2)
59.6 (28.9)
Block Design
29.7 (9.0)
28.2 (8.9)
Benton (copy)
5.6 (1.3)
5.5 (1.8)
Digit Symbol
41.0 (10.9)
38.8 (11.0)
Mental Control
7.2 (1.6)
7.3 (1.7)
Digits Forward
6.8 (1.2)
6.8 (1.2)
Digits Backward
4.9 (1.4)
4.6 (1.3)
Letter Fluency (S & P)
26.5 (9.9)
28.1 (10.7)
Note: All cognitive tests equivalent at baseline testing
*
The 2 patient groups differ at p < .05; degrees of freedom (df) vary slightly due to missing data (median df = 63;
no difference > 3)
†
Trend for difference (t =1.84; p = .07)
a
Score is the reciprocal of the number of seconds to complete multiplied by 100; higher scores indicate better
performance
b
Higher scores indicate poorer performance

Neuropsychological Assessment
This psychometric battery assessed a broad spectrum of abilities (i.e., semantic memory, episodic memory,
working memory, and visuospatial ability) across multiple cognitive domains and previously described in detail29.
It was administered annually to all participants approximately 2 weeks after clinical evaluation.
Psychometricians were not informed of the results of the clinical evaluation, nor did clinicians use the
psychometric data to determine diagnosis or CDR. We used a psychometric strategy that put all patients’ test
scores on a common (comparable) metric relative to their first time-of-assessment. All scores were standardized
(M=0, SD=1) to the patients’ first time of assessment (best performance available) and Trailmaking A was
reversed scored so that a high score on all variables indicated good performance. These standard scores were
also residualized for age, education, and motor speed (Crossing-Off37) thus controlling for these common
covariates. Subtests included: Digit Symbol Substitution,38 Block Design, 38 Benton Visual Retention Test – Copy
(BVRT-Copy), 39 Letter Fluency (S&P),40 Mental Control, 38 Digit Span Forward & Backward, 41 Information,38
Paired Associate Learning,38 Boston Naming,42 and Logical Memory.38

Multiphase Random Changepoint (MRC) Model
We applied a Bayesian estimated MRC model to the longitudinal summary scores of cognitive abilities. This
longitudinal model is a 2-segmented continuous regression that captured the trajectory of a clinical index before
and after a disease-state change has occurred. MRC used a subject specific changepoint, thus allowing for
individual differences in how dementia onsets.43 Estimation was achieved using MCMC to sample from the
posterior distributions; repeated samples from the conditional distributions drawn for each parameter using the
Gibbs sampling algorithm in JAGS44 and the R statistical platform.45 Simulation studies show that these Bayesian
estimation procedures yield highly reliable fixed-effects and Level-1 variance parameters in the MRC model.46
We used the Bayesian estimates of the MRC posterior means for intercepts, slopes, and change-points of pre
and post-clinical PDD stages to characterize individual trajectories of scores relative to disease activity (Figure 1).
Estimates of longitudinal change were not based on time of diagnosis or absolute time of assessment, but rather
time of assessment relative to disease activity. Groups were combined and all raw data aligned at the first nonzero CDR for PDD and at the last available measurement for PDND. Credible intervals (Bayesian equivalent of a
confidence interval) for the pre and post slopes served as criteria to accept/reject the changepoint estimate as
significant and thus clinically meaningful. Only when distributions’ of the slope (β1) in the first phase and the
slope in the second phase (β2) did not contain one another (i.e., fell outside of each other’s 95% credible
intervals) was a changepoint considered to be significant.

Figure 1
Logistic curves (left-side Y-axis scale) represent the predicted clinical thresholds for decline on each of the
subtests sensitive to disease onset. These thresholds are the models’ average departure from the stable state to
the active disease state in participants who eventually develop PDD. They are derived from the probability
densities (right-side Y-axis scale) which represent the cumulative distributions of these models’ estimated timeof- onset for the active disease state (changepoint). In this figure we have convolved the subtests’ distributions
to indicate the 3 proposed epochs. These epochs are based on our previous longitudinal factor analysis using
this sample. Standard errors reflect the sensitivity/specificity of the subtests to detect change (slope of the
logistic curves measured at the threshold).
Epoch I – Working Memory (Long Dashed Lines)
(a) Digit Span - Backwards Subtest of the WMS
(b) Mental Control Subtest of the WMS
Epoch II – Visuospatial Processing (Solid Lines)

(c) Digit Symbol Substitution Subtest of the WMS
(d) Block Design Subtest of the WAIS
(e) Benton Visual Retention Test – Copy
Epoch II – Semantic Memory (Short Dashed Lines)
(f) Information Subtest of the WMS
Model Specification. Let Yij represent the jth measurement time of the ith individual. The models considered
assumed that the Yij were distributed normally with expectation E[Yij] and variance σ2ij. The two phases were
modeled as linear fixed-effects with slopes β1, β2. The transition between the phases is continuous at an
individual’s changepoint, δi. δi was modeled as a random effect. The fixed-effect intercept (α) is interpreted as
the level of the specific measurement at the changepoint. All parameters were assumed to be independent.
Standard uninformative priors were chosen for the fixed effects and for the priors and hyper-priors of the
random effects.

𝑌𝑌𝑖𝑖𝑖𝑖 ~𝑁𝑁(𝐸𝐸[𝑌𝑌𝑖𝑖𝑖𝑖 ], 𝜎𝜎𝑖𝑖𝑖𝑖2 )
𝛼𝛼 + 𝛽𝛽1 (𝑡𝑡𝑖𝑖𝑖𝑖 − 𝛿𝛿𝑖𝑖 ) 𝑡𝑡𝑖𝑖𝑖𝑖 < 𝛿𝛿𝑖𝑖
𝐸𝐸[𝑌𝑌𝑖𝑖𝑖𝑖 ] = {
𝛼𝛼 + 𝛽𝛽2 (𝑡𝑡𝑖𝑖𝑖𝑖 − 𝛿𝛿𝑖𝑖 ) 𝑡𝑡𝑖𝑖𝑖𝑖 ≥ 𝛿𝛿𝑖𝑖

Parameter Specification:
𝛼𝛼, 𝛽𝛽1, 𝛽𝛽2 ~ N (0,1000)
𝛿𝛿𝑖𝑖 ~ N(μi, τi)
𝜇𝜇𝑖𝑖 ~ N (0,1000) < 0
𝜏𝜏𝑖𝑖 ~ Gamma (0.001,0.001)
𝜎𝜎𝑖𝑖𝑖𝑖2 ~Gamma(0.001,0.001)

Results

Demographic information (Table 1) and performance on neuropsychological testing for PDND (n = 25) and PDD
(n = 39) groups from their first assessment (all cognitively normal; CDR 0) indicates that the PDD group (mean
age= 71.5±7.5 yrs) was older at baseline than the PDND group (mean age= 69.3±7.4 yrs). The PDD group
performed significantly worse on all cognitive subtests at their first assessment (all t > 2.29, p < .05). The 2
groups were statically equivalent for level of education (t = 1.84, p = .07); however, PDD trended higher. This
trend is likely an artifact of the sampling process. The original memory and aging program where this patient
population was drawn is highly educated (Range 12 to 24 years), seeks out medical care, and volunteers. Thus
they are not typical of epidemiological sampled populations. Both the PDND and PDD groups were
predominantly male (75%). The average number of years for participant follow up was 6.4 (range = 4–19) in the
PDND group and 7.2 years (range = 4–14) in the PDD group.
This MRC estimated subject-specific intercepts, preclinical slopes, changepoints, and post-changepoint slopes
for both the stable and progressed groups together (Table 2). Of the 12 subtests examined, 6 showed
meaningful prodromal changepoints. For the PDD group, all 6 changepoints reached a threshold for significance,
occurring 2.8 to 5.2 years before the first non-zero CDR. Subtests included Digit Span Backward, Block Design,
BVRT-Copy, Mental Control, Digit Symbol, and Information. In contrast, all 6 of these subtests showed linear
decline in the PDND group because all slopes (first and second phase) fell within each other’s credible intervals.
Table 2. Estimated changepoints (standard error) for each subtest by patient group
Parkinson’s
Dementia

Epoch I – Working
memory
Digit Span Backwards*
Mental Control*
Epoch II –
Visuospatial
Digit Symbol*
Block Design*
BVRT - Copy*
Epoch III – Semantic
Memory
Information*
Non-Significant
Subtests
Logical Memory
Associate Learning
Boston Naming
Trailmaking A
Digits Forward
Word Fluency
Parkinson’s No
Dementia
Digit Span Backwards
Mental Control
Digit Symbol
Block Design
BVRT-Copy
Information
Logical Memory

Intercept
(α)

Slope in
Pre(β1)

Slope in
Post (β2)

Predicted Change(δ) Relative
to Diagnosis

CDR Sum of
Boxes at
Time of
Assessment

0.35 (0.15)

0.01 (0.02)

−0.09 (0.02)

−5.15 (1.79)

3

0.11 (0.14)

0.02 (0.02)

−0.09 (0.03)

−4.45 (2.06)

4

−0.57
(0.22)
0.17 (0.14)
0.02 (0.20)

−0.05
(0.03)
0.01 (0.02)
0.00 (0.03)

−0.15 (0.02)

−4.33 (1.31)

4

−0.16 (0.02)
−0.14 (0.03)

−4.32 (1.13)
−4.15 (1.67)

4
4

0.17 (0.09)

0.04 (0.01)

−0.07 (0.02)

−2.83 (1.31)

6

−0.05
(0.15)
0.07 (0.16)
0.35 (0.23)

0.08 (0.05)

−0.04 (0.02)

−6.65 (1.91)

0.03 (0.02)
−0.03
(0.05)
1.07 (1.58)

−0.06 (0.02)
−0.07 (0.02)

−4.99 (1.97)
−5.71 (2.85)

2.28 (0.70)

−5.82 (2.85)

0.00 (0.04)
−0.12
(0.04)

−0.06 (0.02)
−0.08 (0.03)

−4.87 (2.67)
−3.86 (3.25)

Slope in
Pre(B1)
−0.07
(0.02)
−0.07
(0.02)
−0.19
(0.02)
−0.08
(0.02)
−0.12
(0.03)
−0.06
(0.02)
−0.02
(0.02)

Slope in
Post (B2)
−0.27
(98.17)
−0.27
(98.38)
0.23 (98.20)

Predicted Change(δ ) Relative
to Last Assessment
−0.63 (0.96)

−0.38
(98.83)
2.09 (93.65)

−0.55 (0.59)

0.15 (98.82)

−0.62 (0.93)

−0.27
(99.27)

−0.55 (0.58)

50.52
(8.22)
0.43 (0.15)
0.04 (0.39)

Intercept
(α)
−0.06
(0.16)
−0.28
(0.15)
−1.29
(0.22)
−0.42
(0.13)
5.05 (0.22)
−0.16
(0.16)
−0.22
(0.12)

−0.59 (0.78)
−0.61 (0.83)

−0.72 (0.90)

Associate Learning

−0.32
−0.05
−0.41
(0.15)
(0.021)
(98.84)
Boston Naming
−0.25
−0.05
0.44 (98.84)
(0.14)
(0.02)
Trailmaking A
58.67
1.78 (0.65) −0.68
(5.61)
(85.48)
Digits Forward
−0.06
−0.08
0.44 (98.81)
(0.12)
(0.02)
Word Fluency
−0.54
−0.09
0.39 (98.21)
(0.16)
(0.02)
*Indicates a significant difference between Phase 1 and Phase 2

−0.56 (0.61)
−0.56 (0.59)
−1.38 (2.00)
−0.55 (0.58)
−0.59 (0.83)

During the progression of the PDD group, a domain-by-domain onset of declining performance in 6 cognitive
tests marking a distinct prodromal phase. First were declines in Fluid Intelligence tasks demanding Working
Memory and Visuospatial Processing ability. These declines persisted when controlling for simple motor speed
(Crossing-Off37). The PDD group then declined on a prototypical crystallized intelligence task – the Information
subtest of the WAIS.38 This pattern of decline was similar but not identical to our previous findings from a
longitudinal factor analysis of PD with and without dementia. The previous research created composite scores of
multiple subtests to index change and found that Visuospatial Processing ability declined 2-years on average
before Working Memory declined (both 1–3 years before diagnosis). In contrast here we examined the change
profiles of individual subtests (some of which were not sensitive to PD and its progression to PDD) and found
that Working Memory tasks preceded Visuospatial tasks. However, when the overlap in credible intervals is
examined, the 2-domains are statistically indistinguishable suggesting a continuous disease process that affects
both Working Memory and Visuospatial Processing. Note that what is absent in these analyses is a definable
changepoint in any of the traditional tasks for episodic memory – Logical Memory and Paired Associate Learning.
Inspection of these changepoints and slopes reveal that subtests are declining linearly and are not specific to
any preclinical epoch, nor changing till very near the eventual PDD diagnosis. This suggests that classic tests of
episodic memory may not be sufficient to detect and quantify cognitive decline in PD. In contrast these data
indicate that a decline in accessing crystalized information (Information subtest) is a harbinger of diagnosis, and
may represent the accumulation of Lewy-related pathology (Lewy bodies and/or Lewy neurites) in cortical and
subcortical regions responsible for memory retrieval and mental flexibility. As bradyphrenia is a common
symptom associated with PD, a test such as Information could be used to predict which PD patient is likely to go
on to MCI and subsequent dementia.

Discussion
Our analyses allow us to characterize the longitudinal transition in cognitive decline from PD to PDD. We found 6
of 12 tasks revealed significant changepoints during the longitudinal transition that many represent the PD-MCI
stage. An initial phase showed very shallow or no decline later followed by a cognitively symptomatic state
marked by a significant acceleration of declining test performance. In contrast there was no indication of
cognitive change in any of these 12 subtests for the PDND sample. This is strong evidence for the existence of a
transitional period of PD-MCI before overt PDD where early decline in visuospatial processing and working
memory are commonly seen in PD followed by deficits in crystalized memory before the eventual transition to
dementia. Further, these changes are occurring up to 5 years prior to diagnosis of cognitively symptomatic PD.
The onset and time course of these data also show that PD-MCI is made up of 3 disease-specific epochs, the first
beginning approximately 5 years prior to clinical diagnosis of PDD. Transition of PD to PD-MCI first begins with
mild deficits in Working Memory (Digit Span – Backward, Mental Control,38). This is consistent with clinical
observation and patient reports of slowed thinking and processing (bradyphrenia).47,48 In the next 1–2 years,
individuals transitioning to PD-MCI experience difficulties in visual imagery in problem solving. The visuospatial
deficits appear to be focal and severe because they are affecting a wide range of tests on this cognitive battery

in a very short epoch of disease progression (Block Design,38 Benton Visual Retention,39 and Digit Symbol
Substitution38). In our previous report longitudinal indices of visuospatial ability were the strongest indicators of
change in disease status in this battery of tests. The combined deficits of working memory and visuospatial
abilities make up a core feature of PD-MCI and is discernable in the longitudinal decline described here using
disease state models. Finally, PD-MCI culminates in deficits in retrieval from long term memory changing about 3
years prior to overt PDD. From this pattern, we posit that cognitive change in PD proceeds through problems
with mental flexibility followed by visual-spatial imagery followed by retrieval of well-learned knowledge finally
followed by the overt dementia state with trouble learning new information (i.e. episodic memory deficits)
becoming a prominent feature and suggests a continuous, rather than dichotomous process.
As a function of time, progressive declines in cognitive, motor, function, mood and behavior may cloud the
ability to tease out individual and cumulative cognitive domains affected in PD.8 This is consistent with the
findings of a data reduction study24 that found cognitive testing of PDD resulted in a complex profile of domains
affected and other studies that find complex profiles of poor performance in PD-MCI25–27 By result the
cumulative effect of domain-by-domain cognitive declines becomes a marker of the time in PDD-specific
cognitive decline. Moreover these declines are accumulating quickly (within 1–2 years) and early changes in CDR
staging (see Sum of Boxes in Table 2) need to trigger for more intensive testing. Thus staging may only be
possible if repeated cognitive measures are applied within months and not years of each other. A very early
Working Memory-only decrement precedes Working Memory + Visuospatial decrement which precedes the
cumulative Working Memory + Visuospatial + Long Term Memory decrement that heralds clinical diagnosis of
overt PDD. Use of an episodic memory task (e.g. list learning, paragraph recall, or associate learning) will likely
miss this early decline and falsely classify the individual as cognitively intact when in fact cognitive impairment is
proceeding on a downward course.
MRC and related disease state models provide us a powerful subject-specific temporal segmentation of the pre
and post-clinical stages of a progressive disease. In the current report they have allowed us to probe theories of
disease onset and the relative time course of multiple symptom domains49,50 and to understand the phenotype
of early stages of cognitively symptomatic PD. MRC provide a strong alternative to modelling primary
progressive disease because they do not rely on normative based performance indices that obscure the
progressive course of disease. Further, frequent co-morbidities in this population may impact cognitive and
functional abilities in ways that cannot be taken into account using normative data for age, gender and
education. When disease-related changes are modeled at the level of the individual, resultant indices reveal a
pattern of symptom onset, frequency, severity, and duration that describe the progression of no impairment to
MCI to dementia in PD. The application of subtest cutscores may be useful as threshold markers for each
cognitive domain sampled; however, the overall profile of decline best characterizes PDD.
These findings have several limitations. We would have preferred to use a more sensitive test of motor slowing
than Crossing Off as a statistical control in our analyses. Motor slowing was likely affecting the progressed
group’s subtest performance across the battery at a disproportionately higher rate. Better measures (e.g.,
UPDRS-3 motor scores) would likely yield a better estimation of the effect of motor slowing on cognition. In
spite of its limitations, Crossing Off provided a useful measure of motor speed with relatively little floor effect.
This particular neuropsychological battery lacked more sensitive measures of executive functioning and working
memory. The addition of other executive tests (i.e. Wisconsin Card Sort) 51 and selective attention or inhibition
(i.e. Stroop)52 may increase sensitivity to detect hypothesized decrements in executive functioning in PD-MCI
and PDD not examined in this study.
The next generation of test strategies needs to explore the component processes of PDD decline across multiple
domains. Now that cognitive domains sensitive to PDD-related decline have been established, next generation
testing needs to apply multiples of these types of tests to understand the nature of the domain-specific declines
and gain better sensitivity and specificity for early PDD declines and test explicitly the hypothesis that cognition

declines cumulatively in PDD. It also seems critical to understand in PDD as visuospatial dominant disability as
found here and elsewhere.53–56 For instance, the visuospatial subtests used here are often thought of as tests of
executive function in classical testing theory (e.g., Digit Symbol and Trailmaking-B) but most of them are also
speeded. From a components processes approach these neuropsychological measures are multimodal made up
visuospatial processing (common to all), executive functioning, and speed-of-processing. Our data supports the
evolving hypothesis that PD is frequently a dementing illness that has at its core a long phase of extrapyramidal
motor impairment (bradykinesia) followed by decrements in working memory and processing speed
(bradyphrenia) passing through a PD-MCI stage of visuospatial imagery and memory retrieval deficits before the
development of overt dementia.
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